Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | CC-93269 |
| Trade Name | |
| Synonyms | CC 93269|CC93269|EM901|BCMAxCD3 TCB CC-93269|Alnuctamab|BMS-986349 |
| Drug Descriptions |
CC-93269 is a bispecific T-cell engager (BiTE) that targets the human B-cell maturation antigen (BCMA; TNFRSF17) on tumor cells, and the CD3 antigen on cytotoxic T cell lymphocytes, potentially resulting in tumor cell killing (NCI Drug Dictionary). |
| DrugClasses | CD3 Antibody 119 TNFRSF17 Antibody 22 |
| CAS Registry Number | NA |
| NCIT ID | C156052 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| BMS-986393 + CC-93269 | BMS-986393 CC-93269 | 0 | 1 |
| CC-92480 + CC-93269 + Dexamethasone | CC-92480 CC-93269 Dexamethasone | 0 | 1 |
| CC-93269 | CC-93269 | 0 | 3 |